Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced financial results for its third quarter ended September 30, 2025 and reaffirmed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback